Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial.

Leukemia · 2025 · PMC12133573 · PMID 40240572

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

First, the PRO endpoints were evaluated as an exploratory objective in PhALLCON, and no adjustment was performed for multiple testing, therefore the nominally significant results should be interpreted with caution.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.